1. Home
  2. MIRA vs BGLC Comparison

MIRA vs BGLC Comparison

Compare MIRA & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MIRA Pharmaceuticals Inc.

MIRA

MIRA Pharmaceuticals Inc.

HOLD

Current Price

$1.34

Market Cap

61.1M

Sector

Health Care

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$3.00

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MIRA
BGLC
Founded
2020
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
10.1M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MIRA
BGLC
Price
$1.34
$3.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
136.9K
8.0K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$0.73
$2.01
52 Week High
$2.45
$15.60

Technical Indicators

Market Signals
Indicator
MIRA
BGLC
Relative Strength Index (RSI) 34.76 22.18
Support Level $1.38 $3.02
Resistance Level $1.48 $3.52
Average True Range (ATR) 0.06 0.23
MACD -0.02 -0.07
Stochastic Oscillator 12.17 5.08

Price Performance

Historical Comparison
MIRA
BGLC

About MIRA MIRA Pharmaceuticals Inc.

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: